Bosentan and the endothelin system in congestive heart failure

The endothelin system appears to play an important role in the pathophysiol ogy of congestive heart failure (CHF). Endothelin receptor antagonists repr esent a novel class of agents that are being evaluated for their potential benefits in treating various cardiovascular disorders. Bosentan is an orall y active endothelin receptor antagonist that has been studied for the treat ment of CHE Early clinical experience with bosentan has confirmed some bene fits on hemodynamic parameters in patients with CHE Its role in slowing the progression of the disease and improving survival remains to be elucidated .